INCR 0001493152-26-040354 6-K/A Filing: Aug 27, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K/A

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of August 2026 (Report No. 4)

Commission File Number: 001-40614

INTERCURE LTD.

(Translation of registrant’s name into English)

85 Medinat ha-Yehudim Street

Herzliya, 4676670, Israel

Tel: +972 77 460 5012

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Amendment No. 1 on Form 6-K/A (this “Amendment”) amends the Report of Foreign Private Issuer on Form 6-K furnished by InterCure Ltd. (the “Company”) to Securities and Exchange Commission on August 26, 2026 (the “Original Form 6-K”). The Original Form 6-K inadvertently reported the purchase price per Unit and the exercise price per Ordinary Share underlying the Warrants without accurately giving effect to the Company’s 1-for-5 reverse share split, which became effective on August 24, 2026. This Amendment corrects those amounts. Except as expressly set forth herein, this Amendment does not amend, update or otherwise modify the Original Form 6-K.

As previously disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K furnished on June 22, 2026, the Company entered into a binding term sheet with certain investors relating to a private placement. Subsequently, between August 12, 2026 and August 25, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain investors, including Mr. Alexander Rabinovich, the Company’s Chief Executive Officer and Chairman of the board of directors, relating to a private placement offering (the “Offering”) of 1,579,028 units, each consisting of one ordinary share, no par value, of the Company (an “Ordinary Share”) and one warrant to purchase one Ordinary Share (a “Warrant”), at a purchase price of $4.71 per unit. Each Warrant is exercisable for a period of five years from the date of issuance at an exercise price of $7.07 per Ordinary Share.

The Offering was completed between August 12, 2026 and August 25, 2026; provided, however, that shareholder approval is required solely with respect to the participation of Mr. Rabinovich, who is also the beneficial owner of approximately 25% of the Company’s outstanding Ordinary Shares, in the Offering. The participation of all other investors in the Offering was not subject to shareholder approval.

The gross proceeds to the Company from the Offering were $5.3 million, not including the proceeds from Mr. Rabinovich, which are expected to be approximately $2.1 million. The Company intends to use the proceeds from the Offering for working capital purposes and to rehabilitate the Nir Oz facility of its wholly owned subsidiary, Canndoc Ltd.

The securities issued with respect to the Offering were exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 903 of Regulation S promulgated thereunder. The securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption from registration.

This Report of Foreign Private Issuer on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

The foregoing descriptions of the Securities Purchase Agreement and the Warrants are qualified in their entirety by reference to the full text of the forms of the Securities Purchase Agreement and Warrant, copies of which are filed as Exhibits 10.1 and 4.1, respectively.

Safe Harbor Statement

This Report of Foreign Private Issuer on Form 6-K contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward-looking statements when discussing the receipt of shareholder approval, and the use of the proceeds from the Offering. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the year ended December 31, 2025 filed with the Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website, www.sec.gov, and in subsequent filings made by the Company with the SEC.

Exhibit<br>No.
4.1		Form of Warrant
10.1		Form of Securities Purchase Agreement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	INTERCURE<br>LTD.

Date:<br>August 27, 2026	/s/<br>Amos Cohen
	Amos<br>Cohen
	Chief<br>Financial Officer

Exhibit 4.1

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS, EXCEPT AS SET FORTH BELOW. BY ITS ACQUISITION HEREOF, THE HOLDER, IF NOT A U.S. PERSON: (1) REPRESENTS THAT IT IS NOT A U.S. PERSON AND IS ACQUIRING THESE SHARES IN AN OFFSHORE TRANSACTION; (2) AGREES THAT IT WILL NOT RESELL OR OTHERWISE TRANSFER THESE SHARES EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, (C) INSIDE THE UNITED STATES, TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE ACT, (D) INSIDE THE UNITED STATES, TO AN ACCREDITED INVESTOR THAT, PRIOR TO SUCH TRANSFER, FURNISHES TO THE COMPANY A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THESE SHARES IN THE FORM SATISFACTORY TO THE COMPANY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM THE COMPANY), (E) OUTSIDE THE UNITED STATES, IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULES 904 AND 905 UNDER THE ACT, OR (F) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE ACT (IF AVAILABLE); AND (3) AGREES THAT IT WILL GIVE EACH PERSON TO WHOM THESE SHARES ARE TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN CONNECTION WITH ANY TRANSFER OF THESE SHARES PURSUANT TO CLAUSES (2)(C), (D), (E) OR (F) ABOVE, THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE COMPANY SUCH CERTIFICATIONS, LEGAL OPINIONS, OR OTHER INFORMATION AS THE COMPANY MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION OR IN A TRANSACTION NOT SUBJECT TO THE REGISTRATION REQUIREMENTS OF THE ACT. AS USED HEREIN, THE TERMS ‘OFFSHORE TRANSACTION’, ‘UNITED STATES’, AND ‘U.S. PERSON’ HAVE THE MEANING GIVEN TO THEM BY REGULATION S UNDER THE ACT.

ORDINARY SHARE PURCHASE WARRANT

INTERCURE LTD.

Warrant<br>Shares: [*]	Initial<br>Exercise Date:<br>[*]

THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [___________] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after March 2, 2025 (the “Initial Exercise Date”) and on or prior to the close of business on (New York City time) on [____], 2029 being five (5) years from the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Intercure Ltd., a company formed under the laws of the State of Israel (the “Company”), up to [______] Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

*The Company’s shareholders approved a 1-for-5 reverse share split at the EGM held on August 11, 2026, which is expected to become effective on or about August 24, 2026.

Section 1. Definitions. Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the “Purchase Agreement”), dated [ ], 2026, among the Company and the purchasers’ signatory thereto.

Section 2. Exercise.

a) Exercise of Warrant. The exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver to the Company the aggregate Exercise Price for the shares specified in the applicable Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank. No ink-original Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

b) Exercise Price. The exercise price per Ordinary Share under this Warrant shall be NIS 4.125 [20.63, after giving effect to the Company’s 5:1 reverse split that became effective on August 24, 2026], subject to adjustment hereunder (the “Exercise Price”).

c) Mechanics of Exercise.

i. Delivery of Warrant Shares Upon Exercise. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer Agent to the Holder by crediting the account of the Holder’s or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”) if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144, and otherwise by physical delivery of a certificate, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price is received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Ordinary Shares on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, (i) “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Ordinary Shares as in effect on the date of delivery of the Notice of Exercise and (ii) “VWAP” means, for any date, the price determined by the first of the following clauses that applies: (a) if the Ordinary Shares are then listed or quoted on a Trading Market, the daily volume weighted average price of the Ordinary Shares for such date (or the nearest preceding date) on the Trading Market on which the Ordinary Shares are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Ordinary Shares for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Ordinary Shares is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Ordinary Shares are then reported in The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per Ordinary Share so reported, or (d) in all other cases, the fair market value of an Ordinary Share as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company.

ii. Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

iii. Rescission Rights. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

2

iv. Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section 2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the Holder’s brokerage firm otherwise purchases, Ordinary Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy -In”), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage commissions, if any) for the Ordinary Shares so purchased exceeds (y) the amount obtained by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of Ordinary Shares that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Ordinary Shares having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of Ordinary Shares with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver Ordinary Shares upon exercise of the Warrant as required pursuant to the terms hereof.

v. No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

vi. Charges, Taxes and Expenses. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares, if any.

vii. Closing of Books. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

3

Section 3. Certain Adjustments.

a) Share Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on Ordinary Shares or any other equity or equity equivalent securities payable in Ordinary Shares (which, for avoidance of doubt, shall not include any Ordinary Shares issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding Ordinary Shares into a larger number of shares, (iii) combines (including by way of reverse share split) outstanding Ordinary Shares into a smaller number of shares, or (iv) issues by reclassification of Ordinary Shares any share capital of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Ordinary Shares (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of Ordinary Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

b) [Reserved.]

c) Subsequent Rights Offerings. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells any Ordinary Share Equivalents or rights to purchase shares, warrants, securities or other property pro rata to the record holders of any class of Ordinary Shares (the “Purchase Rights”), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Ordinary Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Ordinary Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

4

d) Pro Rata Distributions. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of Ordinary Shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) except to the extent an adjustment was already made pursuant to Section 3(a) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of Ordinary Shares acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Ordinary Shares are to be determined for the participation in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Ordinary Shares as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).

e) Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii) the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Ordinary Shares or 50% or more of the voting power of the common equity of the Company, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares are effectively converted into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires 50% or more of the outstanding Ordinary Shares (not including any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination) or more than 50% of the voting power of the common equity of the Company (each a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder, the number of Ordinary Shares of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of Ordinary Shares for which this Warrant is exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Ordinary Share in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Ordinary Shares are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the Ordinary Shares acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the Ordinary Shares pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term “Company” under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the “Company” shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3(e) regardless of (i) whether the Company has sufficient authorized Ordinary Shares for the issuance of Warrant Shares and/or (ii) whether a Fundamental Transaction occurs prior to the Initial Exercise Date.

f) Calculations. All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 3, the number of Ordinary Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of Ordinary Shares (excluding treasury shares, if any) issued and outstanding.

5

g) Notice to Holder.

i. Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.

ii. Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Ordinary Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Ordinary Shares, (C) the Company shall authorize the granting to all holders of the Ordinary Shares rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification of the Ordinary Shares, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Ordinary Shares are converted into other securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Ordinary Shares of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Ordinary Shares of record shall be entitled to exchange their Ordinary Shares for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Report on Form 6-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

6

Section 4. Transfer of Warrant.

a) Transferability. Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

b) New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

c) Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

d) Transfer Restrictions. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.

7

e) Representation by the Holder. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

Section 5. Miscellaneous.

a) No Rights as Shareholder Until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3. Without limiting the Company’s obligation to issue Warrant Shares pursuant to Section 2(c)(i) or to make any cash payments expressly required pursuant to Section 2(c)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

b) Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated, the Company will make and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or share certificate.

c) Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.

d) Authorized Shares.

The Company covenants that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Ordinary Shares a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Ordinary Shares may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

8

Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its articles of association or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

e) Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance with the provisions of the Purchase Agreement.

f) Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, will have restrictions upon resale imposed by state and federal securities laws.

g) Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s rights, powers or remedies. Without limiting any other provision of this Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

9

h) Notices. Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement.

i) Limitation of Liability. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Ordinary Share or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.

j) Remedies. The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate.

k) Successors and Assigns. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

l) Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.

m) Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.

n) Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

10

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.

	INTERCURE<br>LTD.

	By:
	Name:	Alex<br>Rabinovich & Amos Cohen
	Title:	CEO<br>& CFO
11
---

NOTICE OF EXERCISE

To: INTERCURE LTD.

(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

[ ] in lawful money of the United States; or

(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:

_______________________________

The Warrant Shares shall be delivered to the following DWAC Account Number:

_______________________________

(1) Purchaser Status. The undersigned is either (i) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act of 1933, as amended; (ii) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act; (iii) is not a U.S; Furthermore, the undersigned is familiar with and understands the terms and conditions and requirements contained in Regulation S, specifically, without limitation, understands that the statutory basis for the exemption claimed for the sale of the Warrant Shares would not be present if the sale, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of the Securities Act.

[SIGNATURE OF HOLDER]

Name of Investing Entity: ________________________________________________________________________

Signature of Authorized Signatory of Investing Entity: _________________________________________________

Name of Authorized Signatory: ___________________________________________________________________

Title of Authorized Signatory: ____________________________________________________________________

Date: ________________________________________________________________________________________

EXHIBIT B

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to

Name:
		(Please<br>Print)

Address:
		(Please<br>Print)

Phone<br>Number:

Email<br>Address:

Dated:<br>_______________ __, ______

Holder’s<br>Signature: _______________________________

Holder’s<br>Address: ________________________________

Exhibit 10.1

SECURITIES PURCHASE AGREEMENT

This Securities Purchase Agreement (this “Agreement”) is dated as of [_____], 2026 (the “Effective Date”) between Intercure Ltd., a company organized under the laws of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of Section 5 of the Securities Act of 1933, as amended (the “Securities Act”) contained in Section 4(a)(2) thereof and/or Regulation S thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement.

NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows:

ARTICLE I.

DEFINITIONS

1.1.	Definitions.<br>In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement,<br>the following terms have the meanings set forth in this Section 1.1:

“Affiliate” means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act.

“Board of Directors” means the board of directors of the Company.

“Business Day” means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States, a legal holiday in the State of Israel or any day on which banking institutions in the State of New York or in the State of Israel are authorized or required by law or other governmental action to close; provided, however, that, for calculating Business Days with respect to any action to be taken by the Company hereunder, Friday after 1:00 p.m. (Tel Aviv time) shall not be considered a Business Day.

“Closing” means the closing of the purchase and sale of the Securities pursuant to Section 2.1.

“Closing Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties thereto, and all conditions precedent to (i) the Purchasers’ obligations to pay the Subscription Amount and (ii) the Company’s obligations to deliver the Securities, in each case, have been satisfied or waived, but in no event later than the third Trading Day following the date hereof.

“Commission” means the United States Securities and Exchange Commission.

“Company Israel Counsel” means Amit, Pollak, Matalon. APM House, 18 Raoul Wallenberg St., Building D, 6th floor, Ramat Hachayal, Tel Aviv, 6971915, Israel..

“Company US Counsel” means Sullivan & Worcester LLP, with offices located at One Post Office Square, Boston, MA 02109.

“Disclosure Schedules” means the Disclosure Schedules of the Company delivered concurrently herewith.

“Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

“IFRS” shall have the meaning ascribed to such term in Section 3.1(c).

“IMCA Approval” means such approval of the Medical Cannabis Unit within the Ministry of Health of Israel as may be required by the applicable rules and regulations with respect to transactions contemplated by the Transaction Documents, including the issuance of any Securities to any IMCA Purchaser.

“IMCA Purchaser” means any Purchaser whose holdings in the Company following the issuance of Securities hereunder (taking into account all Ordinary Shares and Warrant Shares issued to such Purchaser) would equal or exceed five percent (5%) of the Company’s issued and outstanding share capital.

“Legend Removal Date” shall have the meaning ascribed to such term in Section 4.1(c).

“Liens” means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.

“Nasdaq” means the Nasdaq Stock Market LLC or any successor thereto.

“Ordinary Share(s)” means the ordinary shares of the Company, no par value each share, and any other class of securities into which such securities may hereafter be reclassified or changed.

“Person” means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company, joint share company, government (or an agency or subdivision thereof) or other entity of any kind.

“Purchaser Party” shall have the meaning ascribed to such term in Section 4.7.

2

“Purchaser Subscription Amount” shall be the amount to be invested by each Purchaser for the purchase of such number of Units calculated by dividing such amount by the Unit Purchase Price as set forth on the signature page of this Agreement.

“Required Approvals” shall have the meaning ascribed to such term in Section 3.1(a).

“Rule 144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

“Rule 424” means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

“SEC Reports” shall have the meaning ascribed to such term in Section 3.1(c).

“Securities” means the Ordinary Shares, the Warrants and the Warrant Shares.

“Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

“Shareholder Approval” means such approval as may be required by the applicable rules and regulations of Nasdaq and the TASE (or any successors to any of the foregoing) from the shareholders of the Company solely with respect to the participation of Alexander Rabinovich in the transactions contemplated by the Transaction Documents, including the issuance of any Securities to Alexander Rabinovich. For the avoidance of doubt, Shareholder Approval shall not be required as a condition to the participation of any other Purchaser in the transactions contemplated by the Transaction Documents.

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing Ordinary Shares).

“Subscription Amount” means, as to each Purchaser, the aggregate amount to be paid for Ordinary Shares and Warrants, and a ratio of one (1) Warrant for each Ordinary Share purchased hereunder, as specified below such Purchaser’s name on the signature page of this Agreement, in United States dollars or New Israeli Shekels, as applicable, and in immediately available funds.

“TASE” means the Tel Aviv Stock Exchange (or any successor thereto).

“Trading Day” means a day on which the Nasdaq Capital Market is open for trading.

3

“Trading Market” means any of the following markets or exchanges on which the Ordinary Shares are listed or quoted for trading on the date in question: the New York Stock Exchange, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange or the TASE (or any successors to any of the foregoing).

“Transaction Documents” means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and any other documents or agreements executed in connection with the transactions contemplated hereunder.

“Unit Purchase Price” equals USD 0.94 [4.71, after giving effect to the Company’s 5:1 reverse split that became effective on August 24^,^ 2026] per Unit, being the agreed equivalent of NIS 2.75 [13.75, after giving effect to the Company’s 5:1 reverse split that became effective on August 24, 2026] per Unit, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions of Ordinary Shares that occur after the date of this Agreement. Each Unit shall consist of one (1) Ordinary Share and one (1) Warrant.

“Warrant Shares” means the Ordinary Shares issuable upon exercise of the Warrants.

“Warrants” means, collectively, the Ordinary Shares purchase warrants exercisable during a period of five (5) years from the date of their grant at an exercise price equal to NIS 4.125 [20.63, after giving effect to the Company’s 5:1 reverse split that became effective on August 24, 2026] per Ordinary Share delivered to the Purchasers at the Closing in accordance with Section 2.2(a) hereof, which Warrants shall be in the form of Exhibit A attached hereto.

ARTICLE II.

PURCHASE AND SALE

2.1.	Closing.<br>On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially<br>concurrent with the execution and delivery of this Agreement by the parties hereto, the Company<br>agrees to sell, and the Purchasers, severally and not jointly, agree to purchase, up to such<br>aggregate number of Units as shall correspond to an aggregate purchase amount of up to NIS<br>22,000,000 (or the USD equivalent subscribed pursuant hereto and pursuant to any substantially<br>similar securities purchase agreements entered into in connection with the same financing<br>round). Each Purchaser shall deliver to the Company, via wire transfer, immediately available<br>funds equal to such Purchaser’s Subscription Amount as set forth on the signature page<br>hereto executed by such Purchaser, and the Company shall deliver to each Purchaser its respective<br>Units (Ordinary Shares and Warrants), as determined pursuant to Section 2.2(a), and the Company<br>and each Purchaser shall deliver the other items set forth in Section 2.2 deliverable at<br>the Closing. Upon satisfaction of the covenants and conditions set forth in Sections 2.2<br>and 2.3, the Closing shall occur remotely by electronic transfer of the closing documentation<br>or such other location as the parties shall mutually agree.
4
---
2.2.	Deliveries.
---	---

(a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following:

(ii) this Agreement duly executed by the Company; and

(iii) the Ordinary Shares under the Units purchased by such Purchaser; and

(iv) the Warrants registered in the name of such Purchaser to purchase up to a number of Ordinary Shares equal to 100% of such Purchaser’s number of Ordinary Shares per instruction of such Purchaser, subject to adjustment therein; and

(v) the Company’s wire instructions, on Company letterhead and executed by the Chief Executive Officer or Chief Financial Officer.

(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company, the following:

(i) this Agreement duly executed by such Purchaser; and

(ii) such Purchaser’s Subscription Amount, which shall be made available by wire transfer.

2.3.	Closing<br>Conditions.

(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:

(i) the accuracy in all material respects on the Closing Date of the representations and warranties of the Purchasers contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);

(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall have been performed;

(iii) the delivery by each Purchaser of the items set forth in Section 2.2(b) of this Agreement;

(iv) Shareholder Approval shall have been obtained and become effective solely to the extent required in connection with the participation of Alexander Rabinovich in the transactions contemplated by the Transaction Documents, and for the avoidance of doubt, Shareholder Approval shall not constitute a condition to the Closing of any other Purchaser’s participation in the round; and

(v) IMCA Approval shall have been obtained and become effective with respect to any IMCA Purchaser.

5

(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the following conditions being met:

(i) the accuracy in all material respects when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of a specific date therein in which case they shall be accurate as of such date);

(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed; and

(iii) the delivery by the Company of the items set forth in Section 2.2(a) of this Agreement.

ARTICLE III.

REPRESENTATIONS AND WARRANTIES

3.1.

Representations and Warranties of the Company. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and warranties to each Purchaser:

(a) Filings, Consents and Approvals. The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery and performance by the Company of the Transaction Documents, other than: (i) the filings required pursuant to Section 4.4 of this Agreement, (ii) application(s) to each applicable Trading Market for the listing of the Ordinary Shares and Warrant Shares when applicable for trading thereon in the time and manner required thereby, including the filing of a Listing of Additional Shares notice with Nasdaq, (iii) such filings as are required to be made under applicable state securities laws and the Israeli Securities Authority and the TASE, (iv) filings required by the Israeli Registrar of Companies, (v) Shareholder Approval solely to the extent required in connection with the participation of Alexander Rabinovich, and (vi) IMCA Approval if applicable (collectively, the “Required Approvals”).

(b) Issuance of the Securities; Registration. The Securities are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Warrant Shares, when issued in accordance with the terms of the Warrants, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized share capital the maximum number of Ordinary Shares issuable pursuant to this Agreement. As of the Closing Date, the Company shall have sufficient authorized capital stock to issue the Warrant Shares.

6

(c) SEC Reports; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the one year preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents incorporated by reference therein being collectively referred to herein as the “SEC Reports”) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with IFRS accounting principles applied on a consistent basis during the periods involved (“IFRS”), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by IFRS, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal, immaterial, year-end audit adjustments.

(d) Registration Rights. No Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary.

(e) Private Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, no registration under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers as contemplated hereby.

3.2.	Representations<br>and Warranties of the Purchasers. Each Purchaser, for itself and for no other Purchaser,<br>hereby represents and warrants as of the date hereof and as of the Closing Date to the Company<br>as follows (unless as of a specific date therein, in which case they shall be accurate as<br>of such date):
7
---

(a) Organization; Authority. Such Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.

(b) Understandings or Arrangements. Such Purchaser is acquiring the Securities as principal for its own account and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities (this representation and warranty not limiting such Purchaser’s right to sell the Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business. Such Purchaser understands that the Securities are “restricted securities” and have not been registered under the Securities Act or any applicable state securities law (and the Company is not obligated to effect any such registration) and is acquiring such Securities as principal for his, her or its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser’s right to sell such Securities pursuant to a registration statement or otherwise in compliance with applicable federal and state securities laws).

(c) Purchaser Status. (i) At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (a) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act or (b) a “qualified institutional buyer” as defined in Rule 144A(a) under the Securities Act; (ii) is not a U.S. Person; and (iii) is familiar with and understands the terms and conditions and requirements contained in Regulation S, specifically, without limitation, each purchaser understands that the statutory basis for the exemption claimed for the sale of the Ordinary Shares under the Units would not be present if the sale, although in technical compliance with Regulation S, is part of a plan or scheme to evade the registration provisions of the Securities Act.

8

(d) Experience of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

(e) Access to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded (i) the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment.

(f) Certain Transactions and Confidentiality. Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser’s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such Purchaser’s representatives, including, without limitation, its officers, directors, partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction).

(g) General Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any seminar or any other general solicitation or general advertisement.

9

(h) Regulation S. Such Purchaser (i) acknowledges that the certificate(s) representing or evidencing the Ordinary Shares and Warrants underlying the Units shall contain a customary restrictive legend restricting the offer, sale or transfer of any Shares except in accordance with the provisions of Regulation S, pursuant to registration under the Securities Act, or pursuant to an available exemption from registration, (ii) agrees that all offers and sales by the Company of Ordinary Shares and Warrants underlying the Units shall be made pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from, or a transaction not subject to the registration requirements of, the Securities Act, including compliance with the “offering restrictions” requirements under Regulation S, if applicable, (iii) represents that the offer to purchase the Ordinary Shares and Warrants underlying the Units was made by the Company outside of the United States, and the Company was, at the time of the offer and will be, at the time of the sale and is now, outside the United States, (iv) has not engaged in or directed any unsolicited offers to purchase Ordinary Shares under the Units in the United States or to U.S. citizens, (v) is neither a U.S. Person nor a Distributor (as such terms are defined in Rule 902(k) and 902(d), respectively, of Regulation S), and (vii) has not pre-arranged any sale with a purchaser in the United States.

The Company acknowledges and agrees that the representations contained in this Section 3.2 shall not modify, amend or affect such Purchaser’s right to rely on the Company’s representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the future.

ARTICLE IV.

OTHER AGREEMENTS OF THE PARTIES

4.1.	Transfer<br>Restrictions.

(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any transfer of Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing to be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser under this Agreement. Each Purchaser will not, during the period commencing on the date of issuance of the Units and ending on the first anniversary of such date, or such shorter period as may be permitted by Regulation S or other applicable securities law (“Restricted Period”), offer, sell, pledge or otherwise transfer the Shares in the United States, or to a U.S. Person for the account or benefit of a U.S. Person, or otherwise in a manner that is not in compliance with Regulation S. Each Purchaser has not in the United States, engaged in, and prior to the expiration of the Restricted Period will not engage in, any short selling of or any hedging transaction with respect to the Shares, including without limitation, any put, call or other option transaction, option writing or equity swap.

10

(b)

(c) The Purchasers agree to the imprinting, so long as is required by this Section 4.1, of a legend on any of the Securities in the following form:

“THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD WITHIN THE UNITED STATES OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, U.S. PERSONS, EXCEPT AS SET FORTH BELOW. BY ITS ACQUISITION HEREOF, THE HOLDER, IF NOT A U.S. PERSON: (1) REPRESENTS THAT IT IS NOT A U.S. PERSON AND IS ACQUIRING THESE SHARES IN AN OFFSHORE TRANSACTION; (2) AGREES THAT IT WILL NOT RESELL OR OTHERWISE TRANSFER THESE SHARES EXCEPT (A) TO THE COMPANY OR ANY SUBSIDIARY THEREOF, (B) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT, (C) INSIDE THE UNITED STATES, TO A QUALIFIED INSTITUTIONAL BUYER IN COMPLIANCE WITH RULE 144A UNDER THE ACT, (D) INSIDE THE UNITED STATES, TO AN ACCREDITED INVESTOR THAT, PRIOR TO SUCH TRANSFER, FURNISHES TO THE COMPANY A SIGNED LETTER CONTAINING CERTAIN REPRESENTATIONS AND AGREEMENTS RELATING TO THE RESTRICTIONS ON TRANSFER OF THESE SHARES IN THE FORM SATISFACTORY TO THE COMPANY (THE FORM OF WHICH LETTER CAN BE OBTAINED FROM THE COMPANY), (E) OUTSIDE THE UNITED STATES, IN AN OFFSHORE TRANSACTION IN COMPLIANCE WITH RULES 904 AND 905 UNDER THE ACT, OR (F) PURSUANT TO THE EXEMPTION FROM REGISTRATION PROVIDED BY RULE 144 UNDER THE ACT (IF AVAILABLE); AND (3) AGREES THAT IT WILL GIVE EACH PERSON TO WHOM THESE SHARES ARE TRANSFERRED A NOTICE SUBSTANTIALLY TO THE EFFECT OF THIS LEGEND. IN CONNECTION WITH ANY TRANSFER OF THESE SHARES PURSUANT TO CLAUSES (2)(C), (D), (E) OR (F) ABOVE, THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH TO THE COMPANY SUCH CERTIFICATIONS, LEGAL OPINIONS, OR OTHER INFORMATION AS THE COMPANY MAY REASONABLY REQUIRE TO CONFIRM THAT SUCH TRANSFER IS BEING MADE PURSUANT TO AN EXEMPTION OR IN A TRANSACTION NOT SUBJECT TO THE REGISTRATION REQUIREMENTS OF THE ACT. AS USED HEREIN, THE TERMS’OFFSHORE TRANSACTION’, ‘UNITED STATES’, AND ‘U.S. PERSON’ HAVE THE MEANING GIVEN TO THEM BY REGULATION S UNDER THE ACT.

11

(d) Upon the request of any Purchaser and subject to the receipt by the Company of any necessary representations from such Purchaser, certificates evidencing the Ordinary Shares and Warrant Shares shall not contain any legend (including the legend set forth in Section 4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, (ii) following any sale of such Ordinary Shares or Warrant Shares pursuant to Rule 144 (assuming cashless exercise of the Warrants), (iii) if such Ordinary Shares or Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Warrants), without the requirement for the Company to be in compliance with the current public information, including under Rule 144(i) if applicable, required under Rule 144 as to such Ordinary Shares and Warrant Shares and without volume or manner of sale restrictions, or (iv) if such legend is not required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). If all or any portion of a Warrant is exercised at a time when there is an effective registration statement with a current prospectus to cover the resale of the Ordinary Shares or Warrant Shares, or if such Ordinary Shares or Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the Warrants) and the Company is then in compliance with the current public information required under Rule 144 (assuming cashless exercise of the Warrants), or if the Ordinary Shares and Warrant Shares may be sold under Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144, including under Rule 144(i) if applicable, as to such Ordinary Shares and Warrant Shares or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission) then such Ordinary Shares or Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required under this Section 4.1(c), the Company will, no later than the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the transfer agent of a certificate representing Ordinary Shares or Warrant Shares, as applicable, issued with a restrictive legend (such date, the “Legend Removal Date”), deliver or cause to be delivered to such Purchaser a certificate representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the transfer agent that enlarge the restrictions on transfer set forth in this Section 4. Ordinary Shares and Warrant Shares subject to legend removal hereunder shall be transmitted by the transfer agent to the Purchaser by crediting the account of the Purchaser’s prime broker as directed by such Purchaser. As used herein, “Standard Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading Market with respect to the Ordinary Shares as in effect on the date of delivery of a certificate representing Ordinary Shares or Warrants Shares, as the case may be, issued with a restrictive legend.

12
4.2.	Furnishing<br>of Information. Until the earliest of the time that (i) no Purchaser owns Securities<br>or (ii) the Warrants have expired, the Company covenants to maintain the registration of<br>the Ordinary Shares under applicable Section of the Exchange Act and to timely file (or obtain<br>extensions in respect thereof and file within the applicable grace period) all reports required<br>to be filed by the Company after the date hereof pursuant to the Exchange Act even if the<br>Company is not then subject to the reporting requirements of the Exchange Act.
---	---
4.3.	Integration.<br>The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate<br>in respect of any security (as defined in Section 2 of the Securities Act) that would be<br>integrated with the offer or sale of the Securities in a manner that would require the registration<br>under the Securities Act of the sale of the Securities or that would be integrated with the<br>offer or sale of the Securities for purposes of the rules and regulations of any Trading<br>Market such that it would require shareholder approval prior to the closing of such other<br>transaction unless shareholder approval is obtained before the closing of such subsequent<br>transaction.
---	---
4.4.	Securities<br>Laws Disclosure; Publicity. The Company shall file a report on Form 6-K, including the<br>Transaction Documents as exhibits thereto, with the Commission within the time required by<br>the Exchange Act. From and after the issuance of such press release, the Company represents<br>to the Purchasers that it shall have publicly disclosed all material, non-public information<br>delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their<br>respective officers, directors, employees or agents in connection with the transactions contemplated<br>by the Transaction Documents. The Company and each Purchaser shall consult with each other<br>in issuing any other press releases with respect to the transactions contemplated hereby,<br>and neither the Company nor any Purchaser shall issue any such press release nor otherwise<br>make any such public statement without the prior consent of the Company, with respect to<br>any press release of any Purchaser, or without the prior consent of each Purchaser, with<br>respect to any press release of the Company, which consent shall not unreasonably be withheld<br>or delayed, except if such disclosure is required by law, in which case the disclosing party<br>shall promptly provide the other party with prior notice of such public statement or communication.<br>Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser,<br>or include the name of any Purchaser in any filing with the Commission or any regulatory<br>agency or Trading Market, without the prior written consent of such Purchaser, except (a)<br>as required by federal securities law in connection with the filing of final Transaction<br>Documents with the Commission and (b) to the extent such disclosure is required by law or<br>Trading Market regulations, in which case the Company shall provide the Purchasers with prior<br>notice of such disclosure permitted under this clause (b).
---	---
13
---
4.5.	[Reserved]
---	---
4.6.	Reservation<br>of Shares. The Company shall continue to reserve and keep available at all times, free<br>of preemptive rights, a sufficient number of Ordinary Shares for the purpose of enabling<br>the Company to issue Warrant Shares pursuant to any exercise of the Warrants.
---	---
4.7.	Equal<br>Treatment of Purchasers. No consideration (including any modification of any Transaction<br>Document) shall be offered or paid to any Person to amend or consent to a waiver or modification<br>of any provision of the Transaction Documents unless the same consideration is also offered<br>to all of the parties to the Transaction Documents. For clarification purposes, this provision<br>constitutes a separate right granted to each Purchaser by the Company and negotiated separately<br>by each Purchaser, and is intended for the Company to treat the Purchasers as a class and<br>shall not in any way be construed as the Purchasers acting in concert or as a group with<br>respect to the purchase, disposition or voting of the Shares or otherwise.
---	---
4.8.	Independent<br>Participation. Notwithstanding anything to the contrary in this Agreement, any other<br>Transaction Document or any side letter, subscription document or other arrangement relating<br>to the transactions contemplated hereby, the participation, funding, execution, Closing or<br>continued participation of any investor other than Alexander Rabinovich shall not be contingent<br>upon, conditioned upon, or subject to the execution, funding, Closing or continued participation<br>of Alexander Rabinovich. The Company may accept subscriptions from, and consummate the sale<br>of Securities to, any Purchaser or other investor irrespective of whether Alexander Rabinovich<br>executes this Agreement, funds his Subscription Amount, satisfies any condition to Closing<br>or otherwise participates in the financing round. No Purchaser shall have any right to terminate,<br>delay, reduce, rescind or condition its investment on the basis that Alexander Rabinovich<br>does not participate, participates in a different amount or fails to satisfy any condition<br>to Closing.
---	---
4.9.	Exercise<br>Procedures. The form of Notice of Exercise included in the Warrants set forth the totality<br>of the procedures required of the Purchasers in order to exercise the Warrants. No additional<br>legal opinion, other information or instructions shall be required of the Purchasers to exercise<br>their Warrants. Without limiting the preceding sentences, no ink-original Notice of Exercise<br>shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization)<br>of any Notice of Exercise form be required in order to exercise the Warrants. The Company<br>shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with<br>the terms, conditions and time periods set forth in the Transaction Documents.
---	---
14
---
4.10.	Shareholder<br>Approval. On or prior to such date as the Company determines is required in order to<br>satisfy applicable law and the applicable rules and regulations of Nasdaq or the Tel Aviv<br>Stock Exchange (or any successor entities), the Company agrees to use reasonable best efforts<br>to obtain, at a special or annual meeting of the shareholders of the Company (at which a<br>quorum is present) (the “Shareholder Meeting”), such Shareholder Approval as<br>may be required solely in connection with the participation of Alexander Rabinovich in the<br>transactions contemplated by the Transaction Documents, including the issuance of any Securities<br>to Alexander Rabinovich. For the avoidance of doubt, no Shareholder Approval shall be required<br>as a condition to the participation or Closing of any other Purchaser in the round. The Company<br>will prepare and file with the Commission a proxy statement to be sent to the Company’s<br>shareholders in connection with the Shareholder Meeting (the “Proxy Statement”).<br>Subject to the directors’ fiduciary duties, the Proxy Statement shall include the Board<br>of Directors’ recommendation that the holders of Ordinary Shares vote in favor of the<br>Shareholder Approval. Each Purchaser agrees to furnish to the Company information concerning<br>such Purchaser and its affiliates as the Company, on the advice of outside counsel, reasonably<br>determines is necessary for the Proxy Statement, the Shareholder Meeting or any subsequent<br>proxy solicitation, provided, however, that the Purchasers shall not be obligated to provide<br>(i) any information subject to confidentiality, nondisclosure, or similar agreements or which<br>cannot be disclosed under applicable law, (ii) personally identifiable information, (iii)<br>information regarding the limited partners of such Purchaser and (iv) financial information<br>that the Purchaser reasonably deems to be material to its business, as determined in good<br>faith in its sole discretion.
---	---

ARTICLE V.

MISCELLANEOUS

5.1.	Termination.<br>It is hereby clarified and agreed by the Parties that, in the event that any of the closing<br>conditions contained in Section 2.3 hereinabove, including the obtaining of the IMCA Approval,<br>or the obtaining of the Shareholder Approval solely to the extent required for the participation<br>of Alexander Rabinovich, is not fulfilled within a sixty (60) business days period as of<br>the Effective Date (the “Termination Date”), then the Share Issuance to the affected<br>Purchaser or Purchasers may be canceled and the affected Purchasers will have no claim of<br>any kind or nature against the Company and its respective successors, assigns, directors,<br>officers and employees in connection therewith, and each affected Purchaser Subscription<br>Amount (as defined therein), together with an interest at the rate of relevant Accountant<br>General’s interest calculated commencing as of the Closing Date, will be returned to<br>such affected Purchaser within fourteen (14) calendar days from the Termination Date. For<br>the avoidance of doubt, the failure to obtain Shareholder Approval required solely for Alexander<br>Rabinovich shall not affect the validity of any Closing for any other Purchaser and shall<br>not entitle any other Purchaser to cancel, delay or condition its investment.
15
---
5.2.	Fees<br>and Expenses. Except as expressly set forth in the Transaction Documents to the contrary,<br>each party shall pay the fees and expenses of its advisers, counsel, accountants and other<br>experts, if any, and all other expenses incurred by such party incident to the negotiation,<br>preparation, execution, delivery and performance of this Agreement.
---	---
5.3.	Entire<br>Agreement. The Transaction Documents, together with the exhibits and schedules thereto,<br>contain the entire understanding of the parties with respect to the subject matter hereof<br>and thereof and supersede all prior agreements and understandings, oral or written, with<br>respect to such matters, which the parties acknowledge have been merged into such documents,<br>exhibits and schedules.
---	---
5.4.	Notices.<br>Any and all notices or other communications or deliveries required or permitted to be provided<br>hereunder shall be in writing and shall be deemed given and effective on the earliest of:<br>(a) the date of transmission, if such notice or communication is delivered via email attachment<br>at the email address as set forth on the signature pages attached hereto at or prior to 5:30<br>p.m. (New York City time) on a Trading Day, (b) the next Trading Day after the date of transmission,<br>if such notice or communication is delivered via [facsimile at the facsimile number or] email<br>attachment at the email address as set forth on the signature pages attached hereto on a<br>day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading<br>Day, (c) the second (2nd) Trading Day following the date of mailing, if sent by U.S. nationally<br>recognized overnight courier service or (d) upon actual receipt by the party to whom such<br>notice is required to be given. The address for such notices and communications shall be<br>as set forth on the signature pages attached hereto. To the extent that any notice provided<br>pursuant to any Transaction Document constitutes, or contains, material, non-public information<br>regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice<br>with the Commission pursuant to a report on Form 6-K.
---	---
5.5.	Amendments;<br>Waivers. No provision of this Agreement may be waived, modified, supplemented or amended<br>except in a written instrument signed, in the case of an amendment, by the Company and the<br>Purchasers who purchased at least 50.1% in interest of the Ordinary Shares (based on initial<br>Subscription Amounts hereunder) or, in the case of a waiver, by the party against whom enforcement<br>of any such waived provision is sought; provided, that if any amendment, modification or<br>waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the<br>consent of at least 50.1% in interest of such disproportionately impacted Purchaser (or group<br>of Purchasers) shall also be required. No waiver of any default with respect to any provision,<br>condition or requirement of this Agreement shall be deemed to be a continuing waiver in the<br>future or a waiver of any subsequent default or a waiver of any other provision, condition<br>or requirement hereof, nor shall any delay or omission of any party to exercise any right<br>hereunder in any manner impair the exercise of any such right. Any proposed amendment or<br>waiver that disproportionately, materially and adversely affects the rights and obligations<br>of any Purchaser relative to the comparable rights and obligations of the other Purchasers<br>shall require the prior written consent of such adversely affected Purchaser. Any amendment<br>effected in accordance with accordance with this Section 5.5 shall be binding upon each Purchaser<br>and holder of Securities and the Company.
---	---
16
---
5.6.	Headings.<br>The headings herein are for convenience only, do not constitute a part of this Agreement<br>and shall not be deemed to limit or affect any of the provisions hereof.
---	---
5.7.	Successors<br>and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties<br>and their successors and permitted assigns. The Company may not assign this Agreement or<br>any rights or obligations hereunder without the prior written consent of each Purchaser (other<br>than by merger). Any Purchaser may assign any or all of its rights under this Agreement to<br>any Person to whom such Purchaser assigns or transfers any Securities, provided that such<br>transferee agrees in writing to be bound, with respect to the transferred Securities, by<br>the provisions of the Transaction Documents that apply to the “Purchasers.”
---	---
5.8.	No<br>Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties<br>hereto and their respective successors and permitted assigns and is not for the benefit of,<br>nor may any provision hereof be enforced by, any other Person, except as otherwise set forth<br>herein.
---	---
5.9.	Governing<br>Law. All questions concerning the construction, validity, enforcement and interpretation<br>of the Transaction Documents shall be governed by and construed and enforced in accordance<br>with the internal laws of the State of Israel, without regard to the principles of conflicts<br>of law thereof. Each party agrees that all legal proceedings concerning the interpretations,<br>enforcement and defense of the transactions contemplated by this Agreement and any other<br>Transaction Documents (whether brought against a party hereto or its respective affiliates,<br>directors, officers, shareholders, partners, members, employees or agents) shall be commenced<br>exclusively in the state and federal courts sitting in the City of Tel-Aviv. Each party hereby<br>irrevocably submits to the exclusive jurisdiction of the courts sitting in the City of Tel-Aviv,<br>Israel for the adjudication of any dispute hereunder or in connection herewith or with any<br>transaction contemplated hereby or discussed herein (including with respect to the enforcement<br>of any of the Transaction Documents), and hereby irrevocably waives, and agrees not to assert<br>in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction<br>of any such court, that such suit, action or proceeding is improper or is an inconvenient<br>venue for such proceeding. Each party hereby irrevocably waives personal service of process<br>and consents to process being served in any such suit, action or proceeding by mailing a<br>copy thereof via registered or certified mail or overnight delivery (with evidence of delivery)<br>to such party at the address in effect for notices to it under this Agreement and agrees<br>that such service shall constitute good and sufficient service of process and notice thereof.<br>Nothing contained herein shall be deemed to limit in any way any right to serve process in<br>any other manner permitted by law. If either party shall commence an action, suit or proceeding<br>to enforce any provisions of the Transaction Documents, then the prevailing party in such<br>action, suit or proceeding shall be reimbursed by the other party for its reasonable attorneys’<br>fees and other costs and expenses incurred with the investigation, preparation and prosecution<br>of such action or proceeding.
---	---
17
---
5.10.	Survival.<br>The representations and warranties contained herein shall survive the Closing and the delivery<br>of the Securities for the applicable statute of limitations.
---	---
5.11.	Execution.<br>This Agreement may be executed in two or more counterparts, all of which when taken together<br>shall be considered one and the same agreement and shall become effective when counterparts<br>have been signed by each party and delivered to each other party, it being understood that<br>the parties need not sign the same counterpart. In the event that any signature is delivered<br>by [facsimile transmission or by] e-mail delivery of a “.pdf” format data file,<br>such signature shall create a valid and binding obligation of the party executing (or on<br>whose behalf such signature is executed) with the same force and effect as if such [facsimile<br>or] “.pdf” signature page were an original thereof.
---	---
5.12.	Severability.<br>If any term, provision, covenant or restriction of this Agreement is held by a court of competent<br>jurisdiction to be invalid, illegal, void or unenforceable, the remainder of the terms, provisions,<br>covenants and restrictions set forth herein shall remain in full force and effect and shall<br>in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially<br>reasonable efforts to find and employ an alternative means to achieve the same or substantially<br>the same result as that contemplated by such term, provision, covenant or restriction. It<br>is hereby stipulated and declared to be the intention of the parties that they would have<br>executed the remaining terms, provisions, covenants and restrictions without including any<br>of such that may be hereafter declared invalid, illegal, void or unenforceable.
---	---
5.13.	Independent<br>Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser<br>under any Transaction Document are several and not joint with the obligations of any other<br>Purchaser, and no Purchaser shall be responsible in any way for the performance or non-performance<br>of the obligations of any other Purchaser under any Transaction Document. Nothing contained<br>herein or in any other Transaction Document, and no action taken by any Purchaser pursuant<br>hereto or thereto, shall be deemed to constitute the Purchasers as a partnership, an association,<br>a joint venture or any other kind of entity, or create a presumption that the Purchasers<br>are in any way acting in concert or as a group with respect to such obligations or the transactions<br>contemplated by the Transaction Documents. Each Purchaser shall be entitled to independently<br>protect and enforce its rights including, without limitation, the rights arising out of this<br>Agreement or out of the other Transaction Documents, and it shall not be necessary for any<br>other Purchaser to be joined as an additional party in any proceeding for such purpose. Each<br>Purchaser has been represented by its own separate legal counsel in its review and negotiation<br>of the Transaction Documents. It is expressly understood and agreed that each provision contained<br>in this Agreement and in each other Transaction Document is between the Company and a Purchaser,<br>solely, and not between the Company and the Purchasers collectively and not between and among<br>the Purchasers.
---	---
5.14.	Construction.<br>The parties agree that each of them and/or their respective counsel have reviewed and had<br>an opportunity to revise the Transaction Documents and, therefore, the normal rule of construction<br>to the effect that any ambiguities are to be resolved against the drafting party shall not<br>be employed in the interpretation of the Transaction Documents or any amendments thereto.<br>In addition, each and every reference to share prices and Ordinary Shares in any Transaction<br>Document shall be subject to adjustment for reverse and forward share splits, share dividends,<br>share combinations and other similar transactions of the and Ordinary Shares that occur after<br>the date of this Agreement. For the avoidance of doubt, for purposes of this financing round,<br>the Unit Purchase Price is USD 0.94 [4.71, after giving effect to the Company’s<br>5:1 reverse split that became effective on August 24, 2026] per Unit, being<br>the agreed equivalent of NIS 2.75 [13.75, before giving effect to the Company’s 5:1<br>reverse split that became effective on August 24, 2026]. per Unit, and the<br>aggregate financing round contemplated hereby is capped at NIS 22,000,000.
---	---

(Signature Pages Follow)

19

IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

INTERCURE LTD.		Address<br>for Notice:
By:
Name:	Alex Rabinovich & Amos Cohen	E-Mail:<br>[email protected]
Title:	CEO & CFO	[email protected]
With a copy to (which shall not constitute notice):

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK

SIGNATURE PAGE FOR PURCHASER FOLLOWS]

20

[PURCHASER SIGNATURE PAGES TO INTERCURE LTD. SECURITIES PURCHASE AGREEMENT]

IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

Name of Purchaser: ____________________________________________________________

Signature of Authorized Signatory of Purchaser: _____________________________________

Name of Authorized Signatory: ___________________________________________________

Title of Authorized Signatory: ____________________________________________________

Email Address of Authorized Signatory:_____________________________________________

Address for Notice to Purchaser:

Address for Delivery of Securities to the Purchaser (if not same address for notice):

Subscription Amount: $_________________

Purchaser<br>Name	Purchaser<br>Subscription Amount	Number<br>of Units

[Signature pages to be updated as applicable for each Purchaser]

The Company’s shareholders approved a 1-for-5 reverse share split at the EGM held on August 11, 2026, which is expected to become effective on or about August 24, 2026.

21

INCR 6-K/A